Literature DB >> 20413627

Effects of prolactin on TSC2-null Eker rat cells and in pulmonary lymphangioleiomyomatosis.

Yasuhiro Terasaki1, Kinnosuke Yahiro, Gustavo Pacheco-Rodriguez, Wendy K Steagall, Mario P Stylianou, Jilly F Evans, Ameae M Walker, Joel Moss.   

Abstract

RATIONALE: Lymphangioleiomyomatosis, a cystic lung disease of women, is characterized by proliferation of smooth muscle-like lymphangioleiomyomatosis cells, which possess mutations in the tuberous sclerosis complex genes, TSC1/TSC2. Growth factors involved in lymphangioleiomyomatosis cell proliferation are unknown. Prolactin, an important reproductive hormone in women, is known to promote cell proliferation and survival in other tissues.
OBJECTIVES: To determine the role of prolactin in signaling and proliferation in lymphangioleiomyomatosis.
METHODS: Prolactin levels in the sera of patients with lymphangioleiomyomatosis were correlated with clinical status. Components of prolactin signal transduction pathways were assessed in lymphangioleiomyomatosis lesions from human lung explants by real-time reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry. Prolactin effects on proliferation and signaling were quantified in tuberin-deficient and tuberin-expressing rat cells in vitro.
MEASUREMENTS AND MAIN RESULTS: Higher prolactin levels in the sera of patients with lymphangioleiomyomatosis were associated with a faster rate of decline in FEV(1) and an increased history of pneumothorax (P < 0.01). Higher levels of prolactin and prolactin receptor mRNA and immunoreactivity were found in lymphangioleiomyomatosis lesions when compared with vascular smooth muscle cells in the same region of tissue. This was accompanied by evidence of activation of signal transducer and activator of transcription-1 (STAT1), STAT3, p44/42, and p38 mitogen-activated protein kinase. Tsc2(-/-) Eker rat embryonic fibroblasts expressed more prolactin receptor than did Tsc2(+/+) cells, and responded to prolactin with increased proliferation and activation of the same signaling pathways seen in vivo.
CONCLUSIONS: Prolactin may be an important growth factor in the pathogenesis of lymphangioleiomyomatosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20413627      PMCID: PMC2937243          DOI: 10.1164/rccm.200911-1737OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  42 in total

1.  Unmodified prolactin (PRL) and S179D PRL-initiated bioluminescence resonance energy transfer between homo- and hetero-pairs of long and short human PRL receptors in living human cells.

Authors:  Dunyong Tan; David A Johnson; Wei Wu; Lingfang Zeng; Yen Hao Chen; Wen Y Chen; Barbara K Vonderhaar; Ameae M Walker
Journal:  Mol Endocrinol       Date:  2005-02-03

Review 2.  The tuberous sclerosis complex.

Authors:  Peter B Crino; Katherine L Nathanson; Elizabeth Petri Henske
Journal:  N Engl J Med       Date:  2006-09-28       Impact factor: 91.245

3.  Platelet-derived growth factor-induced p42/44 mitogen-activated protein kinase activation and cellular growth is mediated by reactive oxygen species in the absence of TSC2/tuberin.

Authors:  Geraldine A Finlay; Victor J Thannickal; Barry L Fanburg; David J Kwiatkowski
Journal:  Cancer Res       Date:  2005-12-01       Impact factor: 12.701

4.  Interferon-gamma-Jak-Stat signaling in pulmonary lymphangioleiomyomatosis and renal angiomyolipoma: a potential therapeutic target.

Authors:  Nisreen El-Hashemite; David J Kwiatkowski
Journal:  Am J Respir Cell Mol Biol       Date:  2005-06-30       Impact factor: 6.914

Review 5.  Therapeutic potential of S179D prolactin--from prostate cancer to angioproliferative disorders: the first selective prolactin receptor modulator.

Authors:  Ameae M Walker
Journal:  Expert Opin Investig Drugs       Date:  2006-10       Impact factor: 6.206

Review 6.  Lymphangioleiomyomatosis.

Authors:  S R Johnson
Journal:  Eur Respir J       Date:  2006-05       Impact factor: 16.671

7.  S179D prolactin primarily uses the extrinsic pathway and mitogen-activated protein kinase signaling to induce apoptosis in human endothelial cells.

Authors:  Eric K Ueda; Hsin-Lung Lo; Paolo Bartolini; Ameae M Walker
Journal:  Endocrinology       Date:  2006-07-13       Impact factor: 4.736

Review 8.  Lymphangioleiomyomatosis.

Authors:  Angelo M Taveira-DaSilva; Wendy K Steagall; Joel Moss
Journal:  Cancer Control       Date:  2006-10       Impact factor: 3.302

9.  Plasma prolactin concentrations and risk of postmenopausal breast cancer.

Authors:  Shelley S Tworoger; A Heather Eliassen; Bernard Rosner; Patrick Sluss; Susan E Hankinson
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

10.  Genetic and morphologic determinants of pneumothorax in lymphangioleiomyomatosis.

Authors:  Wendy K Steagall; Connie G Glasgow; Olanda M Hathaway; Nilo A Avila; Angelo M Taveira-Dasilva; Antoinette Rabel; Mario P Stylianou; Jing-Ping Lin; Xiaoling Chen; Joel Moss
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2007-07-06       Impact factor: 5.464

View more
  8 in total

Review 1.  Sex-specific lung diseases: effect of oestrogen on cultured cells and in animal models.

Authors:  Bosung Shim; Gustavo Pacheco-Rodriguez; Jiro Kato; Thomas N Darling; Martha Vaughan; Joel Moss
Journal:  Eur Respir Rev       Date:  2013-09-01

Review 2.  The Lymphangioleiomyomatosis Lung Cell and Its Human Cell Models.

Authors:  Wendy K Steagall; Gustavo Pacheco-Rodriguez; Thomas N Darling; Olga Torre; Sergio Harari; Joel Moss
Journal:  Am J Respir Cell Mol Biol       Date:  2018-06       Impact factor: 6.914

Review 3.  Lymphangioleiomyomatosis - a wolf in sheep's clothing.

Authors:  Elizabeth P Henske; Francis X McCormack
Journal:  J Clin Invest       Date:  2012-11-01       Impact factor: 14.808

4.  Role of Prolactin Receptors in Lymphangioleiomyomatosis.

Authors:  Amira Alkharusi; Elena Lesma; Silvia Ancona; Eloisa Chiaramonte; Thomas Nyström; Alfredo Gorio; Gunnar Norstedt
Journal:  PLoS One       Date:  2016-01-14       Impact factor: 3.240

5.  Single-Cell Transcriptomic Analysis Identifies a Unique Pulmonary Lymphangioleiomyomatosis Cell.

Authors:  Minzhe Guo; Jane J Yu; Anne Karina Perl; Kathryn A Wikenheiser-Brokamp; Matt Riccetti; Erik Y Zhang; Parvathi Sudha; Mike Adam; Andrew Potter; Elizabeth J Kopras; Krinio Giannikou; S Steven Potter; Sue Sherman; Stephen R Hammes; David J Kwiatkowski; Jeffrey A Whitsett; Francis X McCormack; Yan Xu
Journal:  Am J Respir Crit Care Med       Date:  2020-11-15       Impact factor: 30.528

Review 6.  The neural crest lineage as a driver of disease heterogeneity in Tuberous Sclerosis Complex and Lymphangioleiomyomatosis.

Authors:  Sean P Delaney; Lisa M Julian; William L Stanford
Journal:  Front Cell Dev Biol       Date:  2014-11-25

7.  Inhibition of Growth of TSC2-Null Cells by a PI3K/mTOR Inhibitor but Not by a Selective MNK1/2 Inhibitor.

Authors:  Jilly F Evans; Ryan W Rue; Alexander R Mukhitov; Kseniya Obraztsova; Carly J Smith; Vera P Krymskaya
Journal:  Biomolecules       Date:  2019-12-24

8.  Histamine signaling and metabolism identify potential biomarkers and therapies for lymphangioleiomyomatosis.

Authors:  Carmen Herranz; Francesca Mateo; Alexandra Baiges; Gorka Ruiz de Garibay; Alexandra Junza; Simon R Johnson; Suzanne Miller; Nadia García; Jordi Capellades; Antonio Gómez; August Vidal; Luis Palomero; Roderic Espín; Ana I Extremera; Eline Blommaert; Eva Revilla-López; Berta Saez; Susana Gómez-Ollés; Julio Ancochea; Claudia Valenzuela; Tamara Alonso; Piedad Ussetti; Rosalía Laporta; Antoni Xaubet; José A Rodríguez-Portal; Ana Montes-Worboys; Carlos Machahua; Jaume Bordas; Javier A Menendez; Josep M Cruzado; Roser Guiteras; Christophe Bontoux; Concettina La Motta; Aleix Noguera-Castells; Mario Mancino; Enrique Lastra; Raúl Rigo-Bonnin; Jose C Perales; Francesc Viñals; Alvaro Lahiguera; Xiaohu Zhang; Daniel Cuadras; Coline H M van Moorsel; Joanne J van der Vis; Marian J R Quanjel; Harilaos Filippakis; Razq Hakem; Chiara Gorrini; Marc Ferrer; Aslihan Ugun-Klusek; Ellen Billett; Elżbieta Radzikowska; Álvaro Casanova; María Molina-Molina; Antonio Roman; Oscar Yanes; Miquel A Pujana
Journal:  EMBO Mol Med       Date:  2021-08-11       Impact factor: 12.137

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.